Status:
RECRUITING
Predicting Cancer Risk With Digital and Molecular Markers
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Breast Cancer
Lung Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and h...
Eligibility Criteria
Inclusion
- Biological adult (at least 18 years old) women
- Written informed consent for study participation and processing of personal data
- Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes
- Additional inclusion criterion for case group:
- Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)
Exclusion
- Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection
- Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4
Key Trial Info
Start Date :
September 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
1250 Patients enrolled
Trial Details
Trial ID
NCT06962670
Start Date
September 14 2024
End Date
December 1 2025
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DigiOnko Präventionsmobil
Please Refer to Project Homepage For Details (see Link Below), Bavaria, Germany